Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres.
作者信息
Gras-Champel Valérie, Liabeuf Sophie, Baud Mariette, Albucher Jean-François, Benkebil Mehdi, Boulay Charlène, Bron Anthony, El Kaddissi Antoine, Gautier Sophie, Geeraerts Thomas, Girot Marie, Grandvuillemin Aurélie, Laujin Hugo, Jonville-Béra Annie-Pierre, Masmoudi Kamel, Massardier Evelyne, Micallef Joëlle, Mounier Céline, Montastruc François, Pariente Antoine, Perez Justine, Raposo Nicolas, Salvo Francesco, Valnet-Rabier Marie-Blanche, Vial Thierry, Massy Nathalie
机构信息
Centre régional de pharmacovigilance, service de pharmacologie clinique, CHU Amiens-Picardie, 80054 Amiens, France.
Centre régional de pharmacovigilance, service de pharmacologie clinique, CHU Amiens-Picardie, 80054 Amiens, France.
出版信息
Therapie. 2021 Jul-Aug;76(4):369-373. doi: 10.1016/j.therap.2021.05.007. Epub 2021 May 19.
Abstract
摘要
相似文献
1
Atypical thrombosis associated with VaxZevria® (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres.与VaxZevria®（阿斯利康）疫苗相关的非典型血栓形成：来自法国地区药物警戒中心网络的数据。
Therapie. 2021 Jul-Aug;76(4):369-373. doi: 10.1016/j.therap.2021.05.007. Epub 2021 May 19.
2
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.2021 年 5 月至 9 月期间，法国开展了一项关于 COVID-19 疫苗 Vaxzevria 不同用途的获益与风险的建模研究。
Euro Surveill. 2021 Jul;26(26). doi: 10.2807/1560-7917.ES.2021.26.26.2100533.
3
Thrombocytopenia and Intracranial Venous Sinus Thrombosis after "COVID-19 Vaccine AstraZeneca" Exposure.接种阿斯利康“新冠疫苗”后出现血小板减少症和颅内静脉窦血栓形成
J Clin Med. 2021 Apr 9;10(8):1599. doi: 10.3390/jcm10081599.
4
Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia.自发性 HIT 综合征：膝关节置换术、感染，与疫苗诱导的免疫性血栓性血小板减少症的相似之处。
Thromb Res. 2021 Aug;204:40-51. doi: 10.1016/j.thromres.2021.05.018. Epub 2021 Jun 9.
5
Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres.药物警戒与药物引起的罕见病：法国区域药物警戒中心网络的优势。
Therapie. 2020 Apr;75(2):207-213. doi: 10.1016/j.therap.2020.02.012. Epub 2020 Feb 13.
6
[The congress of the French Society of Pharmacology and Therapeutics celebrate in Nancy, 20 April 2016, 40 years of French Regional Pharmacovigilance Centres!].[2016年4月20日在南锡举行的法国药理学与治疗学学会大会庆祝法国地区药物警戒中心成立40周年！]
Therapie. 2016 Sep;71(4):351-4. doi: 10.1016/j.therap.2016.05.002. Epub 2016 May 21.
7
Correction to: Assessing Case Fatality on Cases of Thrombosis with Concurrent Thrombocytopenia Following COVID-19 Vaccine AstraZeneca (Vaxzevria) in the United Kingdom: A Review of Spontaneously Reported Data.对《评估英国接种阿斯利康新冠疫苗（Vaxzevria）后并发血小板减少症的血栓形成病例的病死率：对自发报告数据的回顾》的勘误
Drug Saf. 2022 Nov;45(11):1439-1440. doi: 10.1007/s40264-022-01233-9.
8
ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST).ChAdOx1 nCOV-19 疫苗诱导的免疫性血栓性血小板减少症和脑静脉窦血栓形成（CVST）。
BMJ Case Rep. 2021 Jun 16;14(6):e243931. doi: 10.1136/bcr-2021-243931.
9
French Pharmacovigilance Public System and COVID-19 Pandemic.法国药物警戒公共系统与新冠疫情
Drug Saf. 2021 Apr;44(4):405-408. doi: 10.1007/s40264-020-01034-y. Epub 2020 Dec 28.
10
Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries.新兴国家 34 家疫苗制造商的药物警戒及相关实践的景观分析。
Vaccine. 2020 Jul 22;38(34):5490-5497. doi: 10.1016/j.vaccine.2020.06.016. Epub 2020 Jun 24.
引用本文的文献
1
ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review.ChAdOx1新型冠状病毒疫苗与成人血栓形成伴血小板减少综合征：一项系统评价
Adv Pharm Bull. 2023 Nov;13(4):723-735. doi: 10.34172/apb.2023.081. Epub 2023 Apr 29.
2
Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination.新型冠状病毒2感染和新冠疫苗接种后的血液凝固及血栓形成障碍
Biomedicines. 2023 Oct 17;11(10):2813. doi: 10.3390/biomedicines11102813.
3
Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes.异源 ChAdOx1-nCoV19 和 BNT162b2 疫苗接种的安全性和免疫原性：异源 COVID-19 疫苗接种结果的荟萃分析。
Vaccine. 2023 May 2;41(18):3003-3010. doi: 10.1016/j.vaccine.2023.03.056. Epub 2023 Mar 30.
4
COVID-19 vaccines adverse events: potential molecular mechanisms.新型冠状病毒肺炎疫苗不良反应：潜在的分子机制。
Immunol Res. 2023 Jun;71(3):356-372. doi: 10.1007/s12026-023-09357-5. Epub 2023 Jan 6.
5
The winding 12-month journey of the AstraZeneca COVID-19 vaccine since its first administration to humans.阿斯利康 COVID-19 疫苗从首次给人类接种到现在已经过去了 12 个月的曲折历程。
Therapie. 2023 May-Jun;78(3):293-302. doi: 10.1016/j.therap.2022.07.003. Epub 2022 Jul 13.
6
Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial.异源 ChAdOx1/BNT162b2 疫苗接种比同源 ChAdOx1 疫苗接种诱导更强的免疫反应：实用、多中心、三臂、部分随机的 HEVACC 试验。
EBioMedicine. 2022 Jun;80:104073. doi: 10.1016/j.ebiom.2022.104073. Epub 2022 May 23.
7
Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients.接种 COVID-19 疫苗后的血栓栓塞事件：286 例此类事件的系统评价。
Ann Vasc Surg. 2022 Aug;84:12-20.e1. doi: 10.1016/j.avsg.2022.05.001. Epub 2022 May 11.
8
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis.全球2019冠状病毒病疫苗的安全性：一项荟萃分析
Vaccines (Basel). 2022 Apr 12;10(4):596. doi: 10.3390/vaccines10040596.
9
Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims.抗冠状病毒疫苗不会加速人类向非大流行期的过渡，而是会减少大流行的受害者人数。
Inflamm Res. 2022 Jun;71(5-6):521-536. doi: 10.1007/s00011-022-01567-1. Epub 2022 Apr 10.
10
Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.新型冠状病毒病疫苗诱导的免疫性血栓性血小板减少症的血栓形成模式和临床结局：系统评价和荟萃分析。
Int J Infect Dis. 2022 Jun;119:130-139. doi: 10.1016/j.ijid.2022.03.034. Epub 2022 Mar 24.
Zotero 插件